Cargando…

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a highly aggressive malignant subtype of inflammatory myofibroblastoma (IMT) associated with poor prognosis. IMT can occur in various parts of the body, most frequently in the lungs, followed by the mesentery, omentum, retroperitoneum, and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, XiaoQing, Zheng, JingFan, Li, XinYi, Chen, YuYu, Liu, Kang, Li, FangChao, Lu, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585149/ https://www.ncbi.nlm.nih.gov/pubmed/37869075 http://dx.doi.org/10.3389/fonc.2023.1252221

Ejemplares similares

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib
por: Song, Guo-qiang, et al.
Publicado: (2023)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion
por: He, Wenguang, et al.
Publicado: (2022)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022)

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023)

Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
por: Pérot, Gaëlle, et al.
Publicado: (2014)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
por: Ye, Zhifeng, et al.
Publicado: (2023)

An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report
por: Huang, Senmiao, et al.
Publicado: (2023)

Post radiation myofibrosarcoma of hypopharynx
por: Korampalli, T.S., et al.
Publicado: (2013)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
por: Wen, Zhengqi, et al.
Publicado: (2021)

Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma
por: Sun, Haitao, et al.
Publicado: (2023)

Case report: ALK-rearranged spindle and epithelioid cell neoplasms with S100 and CD34 co-expression: Additional evidence of kinase fusion–positive soft tissue tumors
por: Sheng, Shao-Jie, et al.
Publicado: (2022)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
por: Wang, Zhan, et al.
Publicado: (2022)

STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment
por: Rüschoff, Jan H., et al.
Publicado: (2019)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
por: Yang, Yan, et al.
Publicado: (2017)

Myofibrosarcoma Mimicking a Vascular Thrombosis: A Case Report
por: Said, Ryan Bou, et al.
Publicado: (2018)

Mandibular myofibrosarcoma of childhood: Surgical resection & reconstruction with fibula flap
por: Kourelis, Konstantinos, et al.
Publicado: (2015)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion
por: Song, Zhengbo, et al.
Publicado: (2021)

Epithelioid Fibrous Histiocytoma with CARS-ALK Fusion: First Case Report
por: Secco, Léo-Paul, et al.
Publicado: (2023)

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
por: Yang, Shuang, et al.
Publicado: (2023)

Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
por: Ma, Yuxiang, et al.
Publicado: (2022)

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
por: Xiao, Andrew, et al.
Publicado: (2023)

Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report
por: Nakayama, Ryuko, et al.
Publicado: (2018)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

Case Report: ALK-Positive Histiocytosis With KIF5B-ALK Fusion in Cerebrum-Disseminated Lesions in a Child
por: Guo, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_olrgbfbdfgcgnhsaq25u6l5q5s